GGrantIndex
Sort

16,300 grants matching fatty liver disease

Estrogen Administration for the Treatment of NASH in Postmenopausal Women

$733,668
Karen K Miller · Massachusetts General Hospital · R01 · FY2023 · DK

Estrogen Administration for the Treatment of NASH in Postmenopausal Women

$733,668
Karen K Miller · Massachusetts General Hospital · R01 · FY2025 · DK

HIV HCV Coinfection Antiviral Therapy and Fibrosis

$733,577
David L Thomas · Johns Hopkins University · R37 · FY2017 · DA

HIV HCV Coinfection Antiviral Therapy and Fibrosis

$733,577
David L Thomas · Johns Hopkins University · R37 · FY2019 · DA

HIV HCV Coinfection Antiviral Therapy and Fibrosis

$733,577
David L Thomas · Johns Hopkins University · R37 · FY2015 · DA

Paternal Contributions to Metabolic Disease in Offspring: Environment, Epigenetics, and Sperm

$733,550
Mary E Patti · Joslin Diabetes Center · R01 · FY2023 · DK

Pathogenesis of youth onset pre-diabetes and Type 2 diabetes

$733,481
Sonia Caprio · Yale University · R01 · FY2024 · DK

Prevention of Hepatocellular Carcinoma (HCC) Associated with Non-Alcoholic Steatohepatitis (NASH)

$733,441
Laura Beretta · University Of Tx Md Anderson Can Ctr · N01 · FY2018 · CA

Understanding the roles of cardiac NAD pools and therapeutic effects of precursor supplements in heart failure

$733,386
Joseph A. Baur · University Of Pennsylvania · R01 · FY2022 · HL

Them1-Mediated Metabolic Regulation and Pathogenic Role in MASLD

$733,166
David E Cohen · Brigham And Women'S Hospital · R01 · FY2024 · DK

Prospective evaluation of outcomes in cirrhosis of different etiologies: impact of HIV infection and simvastatin therapy

$733,101
Srinivasan Dasarathy · Cleveland Clinic Lerner Com-Cwru · U01 · FY2025 · DK

Prospective evaluation of outcomes in cirrhosis of different etiologies: impact of HIV infection and simvastatin therapy

$733,101
Srinivasan Dasarathy · Cleveland Clinic Lerner Com-Cwru · U01 · FY2024 · DK

Risk Stratification for and Early Detection of Liver Cancer

$732,726
Fasiha Kanwal · Baylor College Of Medicine · U01 · FY2018 · CA

Treating early type 2 diabetes by reducing postprandial glucose excursions: A paradigm shift in lifestyle modification

$732,686
Daniel Joseph Cox · University Of Virginia · R01 · FY2022 · DK

Molecular Genetics, Biochemistry And Therapy Of Pathogenic Fungi

$732,572
John E Bennett · National Institute Of Allergy And Infectious Diseases · Z01 · FY2008 · AI

Leveraging Large-Scale Multi-Ethnic, Multi-Omic Data for Functional Analysis of Central Obesity Loci

$732,261
Stephen S. Rich · University Of Virginia · R01 · FY2025 · HL

A Novel Plasminogen Receptor Promotes Adipose Function and Metabolic Homeostasis

$732,257
Lindsey A Miles · Scripps Research Institute, The · R01 · FY2022 · HL

A Novel Plasminogen Receptor Promotes Adipose Function and Metabolic Homeostasis

$732,257
Lindsey A Miles · Scripps Research Institute, The · R01 · FY2020 · HL

A Novel Plasminogen Receptor Promotes Adipose Function and Metabolic Homeostasis

$732,257
Lindsey A Miles · Scripps Research Institute, The · R01 · FY2021 · HL

Long-term Effects of IDU, HIV, HCV and the Impact of HCV Cure on Immune Activation and Liver Fibrosis in Aging Women

$731,445
Andrea A. Kovacs · University Of Southern California · R01 · FY2017 · DA

Mechanisms for regulation of a novel class of anti-diabetic lipids

$731,406
Barbara B Kahn · Beth Israel Deaconess Medical Center · R01 · FY2024 · DK

Physiologic Consequence of Genetic Variation

$731,183
Richard M Watanabe · University Of Southern California · R01 · FY2020 · DK

Using genetic variation to study biology of blood lipids & coronary heart disease

$730,677
Gina Marie Peloso · Boston University Medical Campus · R01 · FY2024 · HL

Fructose Metabolism Effects on the Liver: Unraveling the Role of Defective Intestinal GNG in Individuals with Obesity

$730,498
Jean-Marc Schwarz · Touro University Of California · R01 · FY2025 · DK

Coronary Artery Calcification in Type 1 Diabetes

$730,404
Marian J. Rewers · University Of Colorado Denver · R01 · FY2007 · HL